Jordyn Sava is an assistant editor for Targeted Oncology.
Updates on Recent Advances and Treatments for Hematologic Malignancies
March 22nd 2023In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.
ISB 1442 Lands FDA Orphan Drug Status for R/R Multiple Myeloma
March 22nd 2023ISB 1442, a 2+1 biparatopic bispecific antibody that has CD38 and CD47 targeting domains, has received an orphan drug designation from the FDA and is being assessed in a phase 1/2 clinical trial for patients with multiple myeloma.
CARTITUDE-1 Update: Cilta-Cel Maintains Benefit in R/R Multiple Myeloma
March 21st 2023At a prespecified analysis of the CARTITUDE-1 trial with a median follow-up of approximately 28 months, treatment with cilta-cel continued to elicit positive responses and maintained a favorable risk/benefit profile for patients with multiple myeloma.
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer
March 20th 2023Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Leveraging ctDNA to Predict Response in Patients With Myeloma Receiving CAR T Cells
March 20th 2023In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.
Coformulation of Pembrolizumab/Vibostolimab Fails to Show PFS Benefit in NSCLC
March 20th 2023The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer
Trial to Assess PRT2527 Plus Zanubrutinib for Hematologic Malignancies
March 18th 2023The combination of CDK9 plus BTK inhibition has already demonstrated synergistic clinical efficacy vs BTK inhibition alone. Now, a clinical trial collaboration will evaluate PRT2527 and zanubrutinib for patients with hematologic malignancies.
Clinicians Must Address Unusual AEs of BRAF/MEK Inhibition for BRAF-Mutated NSCLC
March 17th 2023A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.
FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma
March 16th 2023Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.
Molecular Targets Making Headway in Pediatric Thyroid Cancer Research
March 16th 2023In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.
ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+/HER2- Breast Cancer
March 15th 2023Promising findings from the phase 2 ELAINE-1 and ELAINE-2 trials have led to the start of a phase 3 study where investigators will evaluate lasofoxifene and abemaciclib as a treatment for patients with ER-positive/HER2-negative breast cancer and an ESR1 mutation.
FDA OKs Pegfilgrastim Biosimilar to Decrease Chemo-Associated Febrile Neutropenia
March 10th 2023A comprehensive analytical data package and pharmacokinetic, pharmacodynamic, and immunogenicity study has led the FDA to approve the pegfilgrastim biosimilar pegfilgrastim-cbqv for patients with cancer.
Assessing Amivantamab/Lazertinib for Patients With EGFR-Mutated NSCLC
March 9th 2023Alexander Spira, MD, PhD, FACP, discusses the combination of amivantamab-vmjw and lazertinib for patients with relapsed or refractory EGFR-mutant non–small cell lung cancer and findings presented at the 2022 IASLC World Conference on Lung Cancer.
Pembrolizumab Misses Survival End Points in mCRPC/NSCLC
March 1st 2023The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.
FDA Receives NDA for Niraparib Plus Abiraterone and Prednisone for BRCA+ mCRPC
March 1st 2023Data from the second interim analysis of the phase 3 MAGNITUDE study showed that the addition of niraparib to abiraterone acetate and prednisone prolonged survival for patients with metastatic castration-resistant prostate cancer with BRCA mutations.